Skip to content

Study · Animal study (in vivo) · mouse · 2026

7 results

Enzymatic Stability and Comparative Effects of Kisspeptin-14, Kisspeptin-13 and Kisspeptin-10 on Beta-Cell Function, Glucose Homeostasis and Appetite Regulation.

Spratt JA, Tanday N, McGinn DM, Chukwu CD, Gault VA, Irwin N

Metabolites17 Sept 2026

PMID42783811 (opens in a new tab)PMCIDPMC13609550 (opens in a new tab)DOI10.3390/metabo16090686 (opens in a new tab)PepBankPUB-42783811
Download PDFPubMedAsk about this study
Jump to 7 results

Summary

Background/Objective: Kisspeptin peptides are being increasingly recognised as regulators of metabolism, but whether these actions differ depending on peptide isoform remains unclear. Methods: The current study compared the enzymatic stability and biological effects of kisspeptin-14 (KP-14), kisspeptin-13 (KP-13) and kisspeptin-10 (KP-10) on beta-cell health and function, glucose homeostasis and appetite. Peptide stability was assessed in murine plasma and, following confirmation of KISS1R expression in BRIN-BD11 beta-cells, actions on insulin secretion, beta-cell proliferation and apoptosis were investigated, with additional secretory studies in isolated murine islets. Metabolic effects of KP-14, KP-13 and KP-10 were subsequently evaluated in healthy male and female mice. Results: KP-14 was resistant to plasma degradation, whereas KP-13 and KP-10 underwent N-terminal proteolysis, with KP-13 degradation generating KP-10 amongst other fragment peptides. The kisspeptin peptides exerted modest direct effects on insulin secretion from BRIN-BD11 cells, with KP-13 being the most efficacious, a bioactivity profile that was confirmed in islets. In addition, KP-13 significantly enhanced beta-cell proliferation and protected against cytokine-induced apoptosis, producing superior beta-cell proliferative effects compared to exenatide. Acute administration of all kisspeptin peptides elevated circulating glucose concentrations, and while KP-14 and KP-10 impaired glucose tolerance, KP-13 did not. Interestingly, KP-14 enhanced glucose-stimulated insulin secretion, with KP-13 and KP-10 being devoid of such actions. All kisspeptin isoforms suppressed food intake, although only KP-13, and especially KP-10 administration, led to an inhibition of feeding. Conclusions: Taken together, these data identify KP-13 as possessing the most favourable overall metabolic actions, based on a combination of beneficial actions on beta-cell health and function together with inhibition of feeding and lack of prominent glucose-elevating actions, suggesting possible therapeutic application for type 2 diabetes.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In healthy mice, acute administration of Kisspeptin‑10 elevated circulating glucose concentrations.

    In plain wordsIn healthy mice, a single dose of Kisspeptin‑10 raised blood glucose.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseCirculating glucose after acute dosing
    Study

    mousen: not reported in source

    Healthy male and female mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Acute administration of all kisspeptin peptides elevated circulating glucose concentrations, and while KP-14 and KP-10 impaired glucose tolerance, KP-13 did not.
    1 context sentence
    Summary · context
    Metabolic effects of KP-14, KP-13 and KP-10 were subsequently evaluated in healthy male and female mice.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In healthy mice, Kisspeptin‑10 impaired glucose tolerance.

    In plain wordsIn healthy mice, Kisspeptin‑10 worsened the handling of a glucose load.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseGlucose tolerance
    Study

    mousen: not reported in source

    Healthy male and female mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Acute administration of all kisspeptin peptides elevated circulating glucose concentrations, and while KP-14 and KP-10 impaired glucose tolerance, KP-13 did not.
    1 context sentence
    Summary · context
    Metabolic effects of KP-14, KP-13 and KP-10 were subsequently evaluated in healthy male and female mice.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In healthy mice, Kisspeptin‑10 did not enhance glucose-stimulated insulin secretion, unlike kisspeptin-14.

    In plain wordsIn healthy mice, Kisspeptin‑10 did not boost glucose-triggered insulin release, unlike kisspeptin-14.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeGlucose-stimulated insulin secretion
    Study

    mousen: not reported in source

    Healthy male and female mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Interestingly, KP-14 enhanced glucose-stimulated insulin secretion, with KP-13 and KP-10 being devoid of such actions.
    1 context sentence
    Summary · context
    Metabolic effects of KP-14, KP-13 and KP-10 were subsequently evaluated in healthy male and female mice.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In healthy mice, Kisspeptin‑10 suppressed food intake, and KP-10 especially led to an inhibition of feeding.

    In plain wordsIn healthy mice, Kisspeptin‑10 reduced food intake.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseFood intake
    Study

    mousen: not reported in source

    Healthy male and female mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    All kisspeptin isoforms suppressed food intake, although only KP-13, and especially KP-10 administration, led to an inhibition of feeding.
    1 context sentence
    Summary · context
    Metabolic effects of KP-14, KP-13 and KP-10 were subsequently evaluated in healthy male and female mice.
  5. 05LabEx vivo tissuePharmacokinetics

    In murine plasma, Kisspeptin‑10 underwent N-terminal proteolysis, whereas kisspeptin-14 resisted degradation.

    In plain wordsIn mouse plasma samples, Kisspeptin‑10 was broken down at one end, unlike kisspeptin-14.

    Peptide
    Kisspeptin-10
    Outcome
    Not applicableStability in murine plasma
    Study

    mousen: not reported in source

    Murine plasma
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    KP-14 was resistant to plasma degradation, whereas KP-13 and KP-10 underwent N-terminal proteolysis, with KP-13 degradation generating KP-10 amongst other fragment peptides.
    1 context sentence
    Summary · context
    Peptide stability was assessed in murine plasma and, following confirmation of KISS1R expression in BRIN-BD11 beta-cells, actions on insulin secretion, beta-cell proliferation and apoptosis were investigated, with additional secretory studies in isolated murine islets.
  6. 06LabEx vivo tissueEfficacy outcome

    In isolated murine islets, the bioactivity profile on insulin secretion, with modest effects of the kisspeptin peptides and KP-13 the most efficacious, was confirmed.

    In plain wordsIn isolated mouse islets, Kisspeptin‑10 had a modest effect on insulin release, in line with the cell results.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseInsulin secretion from isolated islets
    Study

    mousen: not reported in source

    Isolated murine islets
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The kisspeptin peptides exerted modest direct effects on insulin secretion from BRIN-BD11 cells, with KP-13 being the most efficacious, a bioactivity profile that was confirmed in islets.
    1 context sentence
    Summary · context
    Peptide stability was assessed in murine plasma and, following confirmation of KISS1R expression in BRIN-BD11 beta-cells, actions on insulin secretion, beta-cell proliferation and apoptosis were investigated, with additional secretory studies in isolated murine islets.
  7. 07LabIn vitro (cells)Efficacy outcome

    In BRIN-BD11 beta-cells, kisspeptin peptides including Kisspeptin‑10 exerted modest direct effects on insulin secretion, with KP-13 the most efficacious.

    In plain wordsIn lab-grown beta-cells, Kisspeptin‑10 had a modest effect on insulin release, smaller than kisspeptin-13.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseInsulin secretion from BRIN-BD11 cells
    Study

    n: not reported in source

    BRIN-BD11 beta-cells
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The kisspeptin peptides exerted modest direct effects on insulin secretion from BRIN-BD11 cells, with KP-13 being the most efficacious, a bioactivity profile that was confirmed in islets.
    1 context sentence
    Summary · context
    Peptide stability was assessed in murine plasma and, following confirmation of KISS1R expression in BRIN-BD11 beta-cells, actions on insulin secretion, beta-cell proliferation and apoptosis were investigated, with additional secretory studies in isolated murine islets.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.